Texas Inspired Drug Discovery Adventures
摘要：This lecture will present a personal story of a 3x cancer survivor and how with the assistance of great coworkers and collaborators an effort has been made to fight back against this disease by studying the chemistry and anti-cancer biology of expanded porphyrins. Expanded porphyrin is a term we introduced into the literature in 1988 to describe larger homologues of natural blood pigments, such as the dyes（e.g., heme） that make blood red. Many expanded porphyrins are now known. They have seen application in areas as diverse as anion recognition（capturing species with negative charges） and extraction（removal of pollutants from waste streams）, photodynamic therapy（where light is used to burn out a cancer）, and aromaticity（a fundamental property of organic chemistry）. In this presentation, the focus will first be on a set of expanded porphyrins called texaphyrins. These compounds were named for the State of Texas due to their size. Two of the texaphyrin complexes, known as MGd and MLu, were the founding technology for Pharmacyclics, Inc., a company that later developed a best-selling leukemia drug and was acquired by Abb Vie for $21B in 2015. New work involving the creation of a new drug lead, oxali TEX-Pt（Ⅳ）, targeting platinum-resistant ovarian cancer, will then be described. Explorations of new gold-based drug leads will also be presented. As time permits work involving other expanded porphyrins from our laboratory will discussed with an emphasis on new work involving actinide（Ⅳ） cation complexation.
The First Asian Conference on Porphyrins, Phthalocyanines, and Related Materials （ACPP-1） & The Sixth National Conference on Porphyrins, Phthalocyanines, and Related Materials （NCPP-6）